Structural
Aortic Valve Disease Learning Series
Late-Breaking Trials and Science
Advertisement
Episodes
ACURATE IDE Trial: Editorial Commentary
8 min.
One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial
22 min.
The ALIGN-AR Trial: Two-Year Outcomes of Transcatheter Aortic Valve Replacement With JenaValve TrilogyTM in High Surgical Risk Patients With Moderate-to-Severe or Severe Native Aortic Regurgitation
15 min.
Transcatheter vs. Surgical Aortic Valve Replacement in Women: A Pooled Analysis of the RHEIA and PARTNER 3 Trials
19 min.
Cerebral Embolic Protection in the US Cohort of the PROTECTED TAVR Trial
18 min.
Comparison of Strategies for Vascular Access Closure After Transcatheter Aortic Valve Implantation: The ACCESS-TAVI Randomized Trial
14 min.
Colchicine in Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement: A Double-Blind Randomized Controlled Trial
15 min.
Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: The TAVR UNLOAD Trial
12 min.
Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Left Ventricular Myocardial Fibrosis
12 min.
Transcatheter Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis: Results of the EARLY TAVR Trial
12 min.
Mid-term Outcomes of Balloon Expandable TAVR for the Treatment of Failed Bioprosthetic Valves in the United States
15 min.
Impact of Bioprosthetic Valve Performance on 5-year Clinical Outcomes in Patients at Intermediate or Greater Surgical Risk
19 min.
Where Do We Go Next?
20 min.
What Data and Valve Design Means for Valve Selection in Women
14 min.
FX+: The Next Step in Addressing Lifetime Management
8 min.
Not All Valves Are Designed Alike
7 min.
Mid-term outcomes of balloon expandable TAVR: do gradients and gender matter?
11 min.
What would a patient consider a good outcome of intervention for symptomatic severe aortic stenosis
15 min.
Which endpoints and definitions matter for assessment of bioprosthetic valve durability following TAVR?
17 min.
The Design of the Navitor Vision Valve
7 min.
Can TAV-in-TAV Simulations be Useful in Procedural Planning?
11 min.
The 2024 'Toolbox' for Leaflet Modification in TAVR
6 min.
How to Interpret the Pathology Data From TAVR Explants
9 min.
The Future is Now! TAVR is a Favorable Alternative in AS Patients Under 65 Years Old
17 min.
Transcatheter Valve Selection for Revalving and Overview of European Trials
9 min.
Projecting the Frequency of Failed Transcatheter Aortic Valves
15 min.
My First Choice Would Be Balloon Expandable Valves!
10 min.
SMART Trial: Supra-Annular Self-Expanding Valves
6 min.
Updates on Randomized Trials in Moderate AS
14 min.
Restoration of flow from CMR: Laminar Flow Impact on Outcomes
21 min.
Clinical Results with the DurAVR THV System
18 min.
Options for a Lifetime and Long-Term Durability
16 min.
Insights of Disabling Stroke from the STS/ACC TVT Registry LBCT
28 min.
Trilogy TAVR in the Real World: An EU Implanter’s Experience with the Trilogy System
17 min.
The Trilogy TAVR System and an Update on the ALIGN-AR Study
19 min.
Overview of Clinical Data on TAVR in Bicuspid AS - What's Needed?
15 min.
The Promise of Next Generation Cerebral Embolic Protection Devices
16 min.
Modern Era Clinical Trial Strategies For Cerebral Embolic Protection Devices
17 min.
Practical Tips for Cerebral Embolic Protection: From Clinical Trials to Clinical Practice
13 min.
Lessons From Off Label TAVR Use in Pure AR – Tips & Tricks
13 min.
Why is TAVR Needed for Chronic Severe AR: Contemporary Insights
10 min.
A Randomized Comparison of TAVR and SAVR in Low-Risk Patients Aged 70 Years or Younger: Results From the NOTION-2 Trial
15 min.
Late Clinical Outcomes With Balloon Expandable Valves in Small Annulus Patients From the PARTNER Trials
15 min.